Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI Dose Reduction and Withdrawal in CML Patients in Deep Molecular Remission
2024-514592-17-00Phase 2Completed
- Sponsor
- Masaryk University
- Start
- Sep 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib, nilotinib and dasatinib in chronic myelogenous leukemia (CML), sponsored by Masaryk University. Primary endpoints: Proportion of patients in major molecular response (MMR) and molecular recurrence-free survival (MRFS) at 6 months, Proportion of patients in major molecular response (MMR) and molecular recurrence-free survival (MRFS) at 12 months and 1 more. Started Sep 2024; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-514592-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514592-17-00.